A phase II trial evaluating the effects of PPAR-gamma agonist (OMS405) in patients with cocaine use disorder (CUD)

Trial Profile

A phase II trial evaluating the effects of PPAR-gamma agonist (OMS405) in patients with cocaine use disorder (CUD)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs OMS 405 (Primary)
  • Indications Cocaine abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2016 New trial record
    • 19 Oct 2016 According to an Omeros Corporation media release, a manucripts detailing the findings has been submitted for publication to a peer-reviewed journal.
    • 19 Oct 2016 Results presented at the 2016 College on Problems of Drug Dependence (CPDD) meeting, according to an Omeros Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top